SUPPLEMENTARY MATERIAL

Supplementary Table 1. Participant characteristics at last visit by Hippocampal Sclerosis of aging and Alzheimer's disease neuropathology (N=1,422), which is operationalized using a relative sensitive method AD-NP(I) which includes Braak stages III and IV.

	No HS-Aging Pathology		HS-Aging Pathology Present		
Characteristic	No AD-NP(I)	Yes AD-NP(I)		Yes AD-NP(I)	
	(n=425)	(n=879)	(n=30)	(n=88)	
	N	N (%)		N(%)	
Age at death (years)					
70-79	78 (18.4)	267 (30.4)	4 (13.3)	14 (15.9)	
80-89	165 (38.8)	418 (47.6)	9 (30.0)	49 (55.7)	
90+	182 (42.8)	194 (22.1)	17 (56.7)	25 (28.4)	
Sex					
Female	204 (48.0)	398 (45.3)	14 (46.7)	42 (47.7)	
Race†					
White	409 (96.5)	837 (95.2)	28 (93.3)	79 (89.8)	
Black	7 (1.7)	30 (3.4)	1 (3.3)	7 (8.0)	
Other	8 (1.9)	12 (1.4)	1 (3.3)	2 (2.3)	
Hispanic ethnicity*	17 (4.0)	31 (3.5)	2 (6.7)	2 (2.3)	
Education*			()		
College graduate	238 (56.0)	476 (54.8)	19 (67.9)	49 (56.3)	
Family History of Dementia*	200 (0010)	., ((
Yes	123 (36.0)	345 (53.6)	7 (29.2)	31 (53.5)	
APOE ε4 alleles*					
0	236 (77.1)	271 (41.6)	16 (76.2)	22 (38.0)	
1	63 (20.6)	297 (45.6	5 (23.8)	28 (47.5)	
2	7 (2.3)	83 (12.8)	0 (0.0)	9 (15.3)	
Cognitive status					
Demented	189 (44.5)	772 (87.8)	21 (70.0)	86 (97.7)	
Primary clinical diagnosis					
Probable AD	95 (22.4)	585 (66.6)	18 (60.0)	80 (90.9)	
Possible AD	40 (9.4)	94 (10.7)	6 (20.0)	3 (3.4)	
Normal	167 (39.3)	45 (5.1)	2 (6.7)	1 (1.1)	
Other	123 (28.9)	155 (17.6)	4 (13.3)	4 (4.6)	
	Mean (SD)		Mean (SD)		
Number of visits to ADC	2.6 (1.4)	2.2 (1.3)	2.9 (1.9)	2.5 (1.4)	
Age of onset † (years)*	80.3 (11.2)	74.3 (8.6)	82.0 (10.3)	74.3 (7.9)	
Duration of cognitive	6.0 (4.1)	8.9 (4.2)	6.9 (3.6)	10.9 (4.2)	
symptoms ⁺ (years)*		~ /		~ /	
CDR-SB at last visit	4.5 (5.5)	11.6 (6.0)	6.8 (5.8)	14.3 (4.9)	

Abbreviations: AD-NP (I), "intermediate to moderate" Alzheimer's disease neuropathology (Braak Stages III- VI and "moderate" or "frequent" CERAD neuritic plaque frequency); CDR-SB, Clinical Dementia Rating "sum of boxes"; HS-Aging, Hippocampal Sclerosis of Aging. *Missing data: race (n=1, <1%), ethnicity (n=4, <1%), education (n=14, <1%), family history (n=354, 25.2%), APOE ε 4 (385, 27.1%), and symptom duration (n=46, 3.7%). † Among participants with MCI or dementia (n=1,227)

Neuropsychological or Clinical Test	β†	95% CI	р
CDR-SB [‡] (N= 689)			
No HS-Aging, no AD-NP			
No HS-Aging, yes AD-NP	-2.5	-3.1, -1.9	<0.001
Yes HS-Aging, no AD-NP	42	-1.88, 1.04	0.57
Yes HS-Aging, yes AD-NP	-3.85	-5.17, -2.54	<0.001
Animal Generation Test (N=609)			
No HS-Aging, no AD-NP			
No HS-Aging, yes AD-NP	-2.52	-3.40, -1.64	<0.001
Yes HS-Aging, no AD-NP	-0.04	-2.12, 2.04	0.97
Yes HS-Aging, yes AD-NP	-3.23	-5.22, -1.23	0.002
Delayed Logical Memory (N=582)			
No HS-Aging, no AD-NP			
No HS-Aging, yes AD-NP	-3.86	-4.60, -3.12	<0.001
Yes HS-Aging, no AD-NP	-3.32	-5.05, -1.60	<0.001
Yes HS-Aging, yes AD-NP	-3.99	-5.67, -2.30	<0.001

Supplementary Table 2. Comparison of Test Scores between Participants with or without HS-Aging and AD-NP (no HS-Aging pathology, no AD-NP chosen as the reference group).*

Abbreviations: CDR-SB, Clinical Dementia Rating "sum of boxes"; HS-Aging, Hippocampal Sclerosis of Aging; AD-NP, Alzheimer's disease neuropathology (Braak Stages V or VI and "moderate" or "frequent" CERAD neuritic plaque frequency).

*Based on linear regression of each test score from a visit 2-5 years prior to death among participants with mild to moderate cognitive impairment, and adjusted for age at death, education and years between visit and death.

[†]A positive β represents a higher functioning compared to participants with no HS-Aging pathology, no AD-NP (reference)

CDR-SB scores were inverted so that an increase in score =higher functioning

Neuropsychological or Clinical Test	β†	95% CI	р
CDR-SB ⁺ ₊ (N= 689)			
Yes HS-Aging Pathology, No AD-NP(I)			
No HS-Aging Pathology, No AD-NP(I)	0.0	-1.98, 1.99	1.00
No HS-Aging Pathology, Yes AD-NP(I)	-2.56	-4.50, -0.61	0.01
Yes HS-Aging Pathology, Yes AD-NP(I)	-3.73	-5.91, -1.56	0.001
Animals Generation Test (N=609)			
Yes HS-Aging Pathology, No AD-NP(I)			
No HS-Aging Pathology, No AD-NP(I)	-0.86	-3.62, 1.90	0.54
No HS-Aging Pathology, Yes AD-NP(I)	-3.38	-6.08, -0.69	0.01
Yes HS-Aging Pathology, Yes AD-NP(I)	-4.16	-7.23, -1.09	0.01
Delayed Logical Memory (N=582)			
Yes HS-Aging Pathology, No AD-NP(I)			
No HS-Aging Pathology, No AD-NP(I)	4.48	2.19, 6.78	<0.001
No HS-Aging Pathology, Yes AD-NP(I)	0.36	-1.88, 2.60	0.75
Yes HS-Aging Pathology, Yes AD-NP(I)	0.0	-2.57, 2.57	1.00

Supplementary Table 3. Comparison of Test Scores between Participants with or without HS-Aging and AD-NP(I).


Abbreviations: CDR-SB, Clinical Dementia Rating "sum of boxes"; HS-Aging, Hippocampal Sclerosis of Aging; AD-NP (I), "intermediate to moderate" Alzheimer's disease neuropathology (Braak Stages III- VI and "moderate" or "frequent" CERAD neuritic plaque frequency).

*Based on linear regression of each test score from a visit 2-5 years prior to death among participants with mild to moderate cognitive impairment, and adjusted for age at death, education and years between visit and death.

 $^{\dagger}A$ positive β represents a higher functioning compared to participants with HS-Aging pathology, no AD-NP

CDR-SB scores were inverted so that an increase in score =higher functioning

Supplementary Figure 1. Study sample flow chart. *Abbreviations:* AD-NP, Alzheimer's disease neuropathology (Braak Stages V or VI and "moderate" or "frequent" CERAD neuritic plaque frequency); CDR-SB, Clinical Dementia Rating "sum of boxes"; FTLD, Frontoemporal lobar degeneration; HS-Aging, Hippocampal Sclerosis of Aging; NP; neuropathology; UDS, Uniform Data Set.



Supplementary Figure 2. Trends by age at death for pathological diagnoses in individuals with dementia. Shown are the primary or contributing <u>pathological</u> diagnosis of Hippocampal Sclerosis of Aging (HS-Aging), "intermediate/moderate" Alzheimer's disease neuropathology (AD-NP(I)), vascular disease, and Lewy bodies charted as a proportion of all pathological diagnoses among participants (70-103 years old at death) with dementia at last visit using fitted curves. (N=1,061).

